Korean J Hematol 1998; 33(3):
Published online September 30, 1998
© The Korean Society of Hematology
건강한 공여자에서 유전자 재조합 인형 과립구 집락 촉진 인자에 의한 말초혈액 CD34+세포의 가동화와 가동화된 CD34+ 세포의 특성
변정래, 정익주, 권상용, 서재성, 최경상, 박무림, 이제중, 김형준
전남대학교 의과대학 내과학교실
Characterization of Peripheral Blood CD34+ Cells Mobilized by Recombinant Human Granulocyte-Colony Stimulating Factor in Healthy Adult Donors
Background: CD34 + cells are capable of engraftment and hematopoietic reconstitution. However, expression patterns of other surface antigens such as CDl3,
CD33, CD38 and HLA-DR on CD34+ cells in mobilized peripheral blood have remained unclear. This study analyzed the expansion kinetics of the CD34+ cells and subsets in the peripheral blood of healthy donors treated with recombinant human Granulocyte Colony-Stimulating Factor(rhG-CSF), the relative
composition of CD34+ subsets in mobilized peripheral blood and apheresis product, the yield of apheresis product.
Methods: The 6 peripheral blood stem cell donors received a daily dose of 500㎍(8.1∼10㎍/kg) of rhG-CSF subcutaneously for 6 or 7 days. The hematologic parameters
and the number of CD34+ cells and subsets in peripheral blood were recorded at baseline and daily for a total 6 to 7 days. With monoclonal antibodies which
were designed for two color direct immnunofluorescence(IF) analysis with combination of fluorescence isothiocyanate (FITC) and phycoerythrin(PE) conjugated, CD34CD38, CD34HLA-DR, CD34CD13, and CD34CD33 surface antigens were analyzed by flow cytometry.
Results: The number of CD34+ cells mobilized to peripheral blood peaked at day 4 or 5 with rhG-CSF treatment. Circulating CD34+ cell expanded by 11.5-fold from 4.5±1.8×10 6/L before rhG-CSF treatment to maxim increment 51.9±13.4×10 6/L after mobilization. Subsets of CD34+CD38-, CD34+HLA-DR-, CD34+CDl3-, and CD34+CD33-(in % of the CD34+ cell) were all decreased and subsets of
CD34+CD38+ , CD34+ HLA-DR+ , CD34<+CD13+ , and CD34+ CD33+ were all increased after mobilization, so that the numbers of early committed and
myeloid committed progenitors were higher than the those of multipotent stem cells in mobilized peripheral blood and leukapheresed products. Each apheresis product yielded a
mean of 451.6×10 6 7.7×10 6 /kg of RBW)
CD34+> cell and 172.3×10 5(2.9×10 5 /kg of RBW) CFU-GM.
Conclusion: Sufficient amount of CD34+cells capable of engraament and hematopoietic reconstitution can be mobilized by administration of rhG-CSF to healthy
adult donor. Subsets of mobilized CD34+ cells were mainly composed of early committed and myeloid committed progenitors, although absolute numbers of all
progenitor cells including multipotent stem cells were significantly increased.
Keywords CD34+ cells; CD34+ subsets; rhG-CSF; Mobilization;
PDF
Standard view
Export citation
Share Article
Korean J Hematol 1998; 33(3): 411-420
Published online September 30, 1998
Copyright © The Korean Society of Hematology.
건강한 공여자에서 유전자 재조합 인형 과립구 집락 촉진 인자에 의한 말초혈액 CD34+세포의 가동화와 가동화된 CD34+ 세포의 특성
변정래, 정익주, 권상용, 서재성, 최경상, 박무림, 이제중, 김형준
전남대학교 의과대학 내과학교실
Characterization of Peripheral Blood CD34+ Cells Mobilized by Recombinant Human Granulocyte-Colony Stimulating Factor in Healthy Adult Donors
Jeong Rae Byun, Ik Joo Chung, Sang Young Kwon, Jae Sung Seo, Kyeoung Sang Choi, Moo Rim Park, Je Jung Lee, Hyeoung Joon Kim
Department of Internal Medicine, Chonnam University Medical School, Kwangju, Korea
Abstract
Background: CD34 + cells are capable of engraftment and hematopoietic reconstitution. However, expression patterns of other surface antigens such as CDl3,
CD33, CD38 and HLA-DR on CD34+ cells in mobilized peripheral blood have remained unclear. This study analyzed the expansion kinetics of the CD34+ cells and subsets in the peripheral blood of healthy donors treated with recombinant human Granulocyte Colony-Stimulating Factor(rhG-CSF), the relative
composition of CD34+ subsets in mobilized peripheral blood and apheresis product, the yield of apheresis product.
Methods: The 6 peripheral blood stem cell donors received a daily dose of 500㎍(8.1∼10㎍/kg) of rhG-CSF subcutaneously for 6 or 7 days. The hematologic parameters
and the number of CD34+ cells and subsets in peripheral blood were recorded at baseline and daily for a total 6 to 7 days. With monoclonal antibodies which
were designed for two color direct immnunofluorescence(IF) analysis with combination of fluorescence isothiocyanate (FITC) and phycoerythrin(PE) conjugated, CD34CD38, CD34HLA-DR, CD34CD13, and CD34CD33 surface antigens were analyzed by flow cytometry.
Results: The number of CD34+ cells mobilized to peripheral blood peaked at day 4 or 5 with rhG-CSF treatment. Circulating CD34+ cell expanded by 11.5-fold from 4.5±1.8×10 6/L before rhG-CSF treatment to maxim increment 51.9±13.4×10 6/L after mobilization. Subsets of CD34+CD38-, CD34+HLA-DR-, CD34+CDl3-, and CD34+CD33-(in % of the CD34+ cell) were all decreased and subsets of
CD34+CD38+ , CD34+ HLA-DR+ , CD34<+CD13+ , and CD34+ CD33+ were all increased after mobilization, so that the numbers of early committed and
myeloid committed progenitors were higher than the those of multipotent stem cells in mobilized peripheral blood and leukapheresed products. Each apheresis product yielded a
mean of 451.6×10 6 7.7×10 6 /kg of RBW)
CD34+> cell and 172.3×10 5(2.9×10 5 /kg of RBW) CFU-GM.
Conclusion: Sufficient amount of CD34+cells capable of engraament and hematopoietic reconstitution can be mobilized by administration of rhG-CSF to healthy
adult donor. Subsets of mobilized CD34+ cells were mainly composed of early committed and myeloid committed progenitors, although absolute numbers of all
progenitor cells including multipotent stem cells were significantly increased.
Keywords: CD34+ cells, CD34+ subsets, rhG-CSF, Mobilization,
Previous Article
